01349 復旦張江
公司資料 - 損益表
上海復旦張江生物醫藥股份有限公司 股票編號: 01349
SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO. LTD. 集團網址: http://www.fd-zj.com
2026/06 - 中期
人民幣(¥)
與去年中期比較 2025/12
人民幣(¥)
2024/12
人民幣(¥)
2023/12
人民幣(¥)
2022/12
人民幣(¥)
營業額 / 收益372,225,274-4.578%685,797,316709,404,966850,733,2121,031,159,838
銷售成本(31,157,945)-21.662%--------
毛利341,067,329-2.638%--------
 
投資物業公平值變動及減值------------
其他項目公平值變動及減值1,018,743-95.657%22,426,4442,791,142(32,643,827)(525,041)
出售項目溢利 / (虧損)9,446-95.348%220,50629,905295,3461,921,767
其他非經營項目------------
分佔聯營公司及共同控制公司業績(4,186,450)96.366%(25,095,447)(28,553,238)(23,539,527)(20,399,820)
除稅前溢利 / (虧損)36,780,123554.194%(155,851,308)5,457,93097,528,063132,293,548
稅項0--(1,872,270)33,976,14210,921,7954,978,650
已終止經營業務溢利 / (虧損)------------
非控股權益114,86723.590%284,080299,824177,510724,900
其他項目------------
股東應佔溢利 / (虧損)36,894,990545.566%(157,439,498)39,733,896108,627,368137,997,098
 
淨財務支出 / (收入)(409,004)4.405%(2,191,616)(5,034,580)(3,703,638)(8,788,607)
折舊及攤銷37,464,041-10.240%78,651,76182,219,82662,232,22582,189,146
董事酬金1,997,87014.361%3,834,4503,903,6704,915,6509,628,686
 
核數師意見不適用--無保留意見無保留意見無保留意見無保留意見
 
市場價值指標
每股盈利 (仙)4.000---15.0004.00011.00013.000
每股派息 (仙)0.000--0.0005.0007.0007.000
派息比率 (%)------125.000%63.636%53.846%
每股現金流 ($)----0.136-0.0160.0690.160
每股帳面資產淨值 ($)2.077--2.0422.2232.2742.193
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.